Thermosome is developing drug candidates leveraging its proprietary drug delivery technology,
Thermosome is an emerging biopharmaceutical company headquartered in the Innovation and Start-Up Center for Biotechnology (IZB) in Planegg/Martinsried near Munich, Germany. Our technology was invented by Prof. Dr. Hansjörg Eibl at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany, and applied, among others, in various in vitro and in vivo studies by a research group at the University Hospital of the Ludwig-Maximilians-Universitaet Munich, Germany. Based on inspiring results from this research including the preclinical proof-of-concept in various animal species, Thermosome started its operational activities in late 2015.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 6, 2016 | Seed | €1.90M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Bayern Kapital | — | Seed |